Literature DB >> 29093394

Mycobacterium bovis-induced Aneurysm after Intravesical Bacillus Calmette-Guérin Therapy: A Case Study and Literature Review.

Yoshitsugu Higashi1, Shigeki Nakamura2, Kento Kidani1, Kaoru Matumoto1, Koyomi Kawago1, Junko Isobe3, Junichi Kanatani3, Yukio Kawagishi4, Ippei Sakamaki1, Yoshihiro Yamamoto1.   

Abstract

Mycobacterium bovis infection after intravesical Bacillus Calmette-Guérin (BCG) therapy is rare. A 65-year-old Japanese man with history of bladder cancer and intravesical BCG therapy, presented with low-grade fever. An aneurysm with perianeurysmal fluid was suspected and endovascular aortic repair was performed. After 160 days, he developed blood-streaked sputum and computed tomography images revealed that the perianeurysmal fluid area was increasing in size. A multiplex polymerase chain reaction using sputum identified M. bovis. Treatment with anti-tuberculosis drugs reduced the size of the perianeurysmal fluid area. After intravesical BCG therapy, the possibility of M. bovis infection should be considered, thus further investigations are required.

Entities:  

Keywords:  Bacillus Calmette-Guérin therapy; Mycobacterium bovis; aortic aneurysm; multiplex polymerase chain reaction

Mesh:

Substances:

Year:  2017        PMID: 29093394      PMCID: PMC5827329          DOI: 10.2169/internalmedicine.9102-17

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


Introduction

Bacillus Calmette-Guérin (BCG) intravesical therapy is widely used for the treatment of superficial bladder cancer. The exact mechanisms underlying the antitumor effects of BCG are unknown. The intravesical instillation of BCG triggers a variety of local immune responses that may persist for a number of months and which appear to be correlated with antitumor activity (1, 2). Its efficacy as an immunotherapy drug has been demonstrated in the treatment of bladder cancer and as prophylaxis against local recurrence (3). In 2006, it was estimated that there were 16,510 cases of bladder cancer in Japan; approximately 70% of untreated cases of bladder cancer involved non-muscular invasive bladder cancer, for which BCG therapy might have been appropriate (4). Intravesical BCG instillation is generally considered safe. Lamm et al., reported that the most common complications of intravesical BCG instillation are high fever (2.9%), hematuria (1%), and infectious granulomatous complications, such as hepatitis (0.5%) and pneumonia (0.5%) (5). However, some cases of life threatening BCG sepsis have been reported (5). Mycobacterium bovis infection of an aortic aneurysm after intravesical BCG therapy is an extremely rare complication. In this report, we document the case of a 65-year-old man who developed a ruptured aortic aneurysm due to M. bovis infection after intravesical BCG therapy.

Case Report

A 65-year-old Japanese man was admitted to a different institution with low-grade fever, which had persisted for 31 days, 13 days before his admission to our hospital. He did not have any other symptoms, and chest radiography and abdominal computed tomography (CT) images were not suggestive of any abnormal findings. However, chest CT images revealed a thoracic saccular aneurysm with perianeurysmal fluid. No evidence of the aneurysm was found on CT images taken 11 months earlier. Since the possibility of an infected aneurysm could not be denied based on the CT findings or the patient's symptoms, ampicillin/sulbactam (ABPC/SBT) was administered at a conventional dose of 3 grams every 6 hours [10 days before admission, ABPC/SBT was replaced by meropenem (1 gram every 6 hours)]. Two sets of blood cultures were obtained before antibiotic treatment was initiated; both returned negative results. Twelve days after the initiation of antibiotics, the patient complained of sudden back pain and progressed to hypovolemic shock. Repeat CT images revealed a ruptured thoracic aortic aneurysm, measuring 2.5×1.9 cm, with pleural effusion that indicated hemothorax (Fig. 1). He was therefore transferred to our hospital.
Figure 1.

Chest radiography and computed tomography images obtained on the day of admission to our hospital. (A) Chest radiography shows left pleural effusion. (B) Chest computed tomography images reveal a ruptured thoracic aortic aneurysm (white arrow), measuring 2.5×1.9 cm, with pleural effusion that suggested hemothorax.

Chest radiography and computed tomography images obtained on the day of admission to our hospital. (A) Chest radiography shows left pleural effusion. (B) Chest computed tomography images reveal a ruptured thoracic aortic aneurysm (white arrow), measuring 2.5×1.9 cm, with pleural effusion that suggested hemothorax. Upon admission, a physical examination revealed the following: body temperature, 36.2℃; blood pressure, 74/52 mmHg; heart rate, 78 beats/min; regular respiratory rate, 24 breaths/min. Respiratory tract sounds were not audible in the left lung. He had no peripheral lymphadenopathy, skin lesions, or neurological deficits, and cardiovascular and the abdominal examinations were unremarkable. His laboratory findings were as follows: white blood cells, 4,930 /μL; hemoglobin, 5.9 g/dL; platelets, 5.5×104/μL; C-reactive protein, 1.45 mg/dL; serum total protein, 5.3 g/dL; albumin, 3.5 g/dL; lactate dehydrogenase, 138 IU/L; aspartate aminotransferase, 123 IU/L; alanine aminotransferase, 33 IU/L; gamma-glutamyltransferase, 18 IU/L; blood urea nitrogen, 14 mg/dL; and creatinine, 0.65 mg/dL. An interferon-gamma release assay (T-SPOT.TB™) yielded a negative result. We revisited the patient's history of bladder cancer. He had received six courses of intravesical BCG therapy [BCG Tokyo 172; BCG (80 mg) was injected through a catheter into the patient's bladder every week for 6 weeks] 12 months previously. He had fever immediately after his sixth course of BCG. Based on his medical history, we performed culturing and polymerase chain reactions (PCRs) using blood, urine, pleural effusion, and bone marrow aspiration specimens, in order to test for Mycobacterium tuberculosis (M. tuberculosis) complex; however, these tests yielded negative results. Blood was cultured for M. tuberculosis complex with a method using 2,3-diphenyl-5-thienyl-(2)-tetrazolium chloride (STC). In view of his medical problems, open surgery was considered too risky. He was therefore treated with thoracic endovascular aortic repair and gauze packing in the left intrathoracic space. If his condition worsened, anti-tuberculosis treatment would have been administered. However, his condition improved following the initiation of treatment, and the antibiotics that were administered by the previous institution, were discontinued at 10 days after admission because the patient's blood and pleural effusion bacterial cultures were negative. Sixty-one days after admission, gauze removal surgery was performed, and the patient was discharged on the 83rd day after admission. During admission, he developed thrombocytopenia and was diagnosed with idiopathic thrombocytopenic purpura. Oral prednisone was initiated at a total daily dose of 60 mg and his overall condition appeared to stabilize over the 5 months that followed, leading to the discontinuation of the medication. One hundred sixty days after admission, he developed blood-streaked sputum. His sputum was tested for M. tuberculosis using acid-fast staining and a PCR; both tests were positive. The isolate identified as M. tuberculosis complex was examined using a multiplex PCR analysis of the cfp32 gene and regions of difference 1, 9, 12, and 16. The methods employed by Chikamatsu et al. were used and in doing so the investigators identified BCG Tokyo172 (6) (Fig. 2). Conclusively, the acid-fast bacilli culture of the sputum grew M. bovis. The minimum inhibitory concentrations (MICs) of the anti-microbial agents against M. bovis was determined using BrothMIC MTB-I (Kyokuto Pharmaceutical Industrial, Tokyo, Japan) and the KYOKUTO PZA test, was as follows: rifampicin, ≤0.031 mg/L; isoniazid, 0.125 mg/L; etambutol, 1.0 mg/L; levofloxacin, 0.5 mg/L. However, the M. bovis was resistant to pyrazinamide. Chest radiography and CT images revealed neither infiltrative changes nor nodules; however, the low attenuation area surrounding the aortic graft was increasing in size and there adhesion to the left lower lobe of the lung was suspected (Fig. 3). Anti-tuberculosis treatment with rifampicin (600 mg, once daily), isoniazid (300 mg, once daily) and etambutol (750 mg, once daily) resulted in the resolution of the patient's symptoms and follow-up chest CT performed 6 months after the development of blood-streaked sputum showed a decrease in the size of the low attenuation mass surrounding the aortic graft.
Figure 2.

The multiplex polymerase chain reaction to test for Mycobacterium bovis (M. bovis) (M: marker, ①, ②: the patient sample isolated from sputum, ③: Non-tuberculosis mycobacterium, ④: Bacillus Calmette-Guérin (BCG) Tokyo 172, ⑤: Mycobacterium tuberculosis (M. tuberculosis), ⑥: Negative control). (A) The isolates identified as M. bovis or Mycobacterium caprae by a multiplex polymerase chain reaction of cfp32 and region of difference 9 and 12. (B) The isolates identified as BCG by a polymerase chain reaction of region of difference 1 (region of difference 1: BCG: 200 bp, other M. tuberculosis complex: 150 bp). (C) The isolates were identified as BCG Tokyo 172 by region of difference 16 (the size of region of difference 16 in BCG Tokyo 172 is unique).

Figure 3.

The clinical course. These images revealed that the low attenuation mass surrounding the aortic graft was increasing (white arrows) with time. The gauze in the intrathoracic space is represented by a white circle. ABPC/SBT: ampicillin/sulbactam, EB: etambutol, INH: isoniazid, RFP: rifampicin

The multiplex polymerase chain reaction to test for Mycobacterium bovis (M. bovis) (M: marker, ①, ②: the patient sample isolated from sputum, ③: Non-tuberculosis mycobacterium, ④: Bacillus Calmette-Guérin (BCG) Tokyo 172, ⑤: Mycobacterium tuberculosis (M. tuberculosis), ⑥: Negative control). (A) The isolates identified as M. bovis or Mycobacterium caprae by a multiplex polymerase chain reaction of cfp32 and region of difference 9 and 12. (B) The isolates identified as BCG by a polymerase chain reaction of region of difference 1 (region of difference 1: BCG: 200 bp, other M. tuberculosis complex: 150 bp). (C) The isolates were identified as BCG Tokyo 172 by region of difference 16 (the size of region of difference 16 in BCG Tokyo 172 is unique). The clinical course. These images revealed that the low attenuation mass surrounding the aortic graft was increasing (white arrows) with time. The gauze in the intrathoracic space is represented by a white circle. ABPC/SBT: ampicillin/sulbactam, EB: etambutol, INH: isoniazid, RFP: rifampicin

Discussion

Infected aortic aneurysms are a rare form of aneurysm (0.9-1.3%) but result in serious clinical conditions and high mortality (7, 8). The most common causative pathogen is Staphylococcus aureus,followed by Streptococcus spp., Salmonella, and Escherichia coli (9). M. bovis includes several mycobacteria of the M. tuberculosis complex, which are closely related and pathogenic. It has a wide range of wild and domestic animal hosts; in the United States during 2006-2013, it caused 1.3-1.6% of culture-confirmed cases of tuberculosis in humans (10). BCG was recommended as a vaccine for tuberculosis and bladder cancer, following the evaluation of its efficacy and safety in clinical trials conducted in France in 1921. However, BCG-related infectious complications may occur following vaccination and intravesical BCG therapy. To our knowledge, in addition to our patient, the literature contains reports on a total of 29 patients with aneurysms infected by M. bovis after intravesical BCG therapy (11-36) (Table). According to these reports, all of the cases occurred in adults [mean age±standard deviation (SD): 71.1±5.46 years], and 28 of the 29 patients were males. The median time interval (±SD) between the last instillation and the onset of infection was 17 months (±15.9). Among the 21 patients who were reported to have complications when BCG was administered, fever was observed in 14 (66.6%); this frequency was higher than that reported in a review of 2,602 (2.9%) patients who were treated with intravesical BCG (5). Among the 29 patients with M. bovis-infected aneurysms, 22 (75.9%) exhibited underlying disease, 6 (27.3%) had at least one risk factor for arterial sclerosis [hypertension (n=5), diabetes mellitus (n=2), and dyslipidemia (n=2)], 12 (54.5%) had a history of coronary artery disease or aneurysm, and 6 (27.3%) had a history of smoking. All patients exhibited at least one symptom; fever was observed in 14 (48.3%) patients while pain was observed in 23 (79.3%) patients. Lee et al., reported that the imaging features of infected aneurysms included lobulated vascular masses, indistinct, irregular arterial walls, perianeurysmal edema, and perianeurysmal soft-tissue masses (37). However, it was difficult to distinguish atherosclerotic aneurysms in some patients.
Table.

Twenty Nine Reported Cases of Infected Aneurysm by Mycobacterium Bovis.

CaseSexAgeMain underlying diseases excluding bladder cancerThe complication caused by BCG injectionLocationInterval*(month)Main symptomsThe method of diagnosis (infection by BCG)OutcomeReferences
1W62Malignant melanomaBacteremiaInfrarenal aorta17Back painCulture of aneurysm specimenRecovered10
2M74UnknownFever and pain localized at the bladderFemoral artery21lumbar painCulture of pelvic collection and thrombusRecovered11
3M67NoneFever, hypotension and anuriaAbdominal aorta, iliac artery14Fever, dysuria, and dullPathology of autopsy specimenDied12
4M69AneurysmMild urgency and frequency of urinationAortic arch36Confusion, weight loss, and fatigueCulture of autopsy specimenDied13
5M80UnknownFever and rigorsInfrarenal aorta24Back painCulture of fluid surrounding aortic graftRecovered14
6M71AneurysmMalaiseAbdominal aorta26Fever and malaiseCulture of aneurysm specimenRecovered15
7M76Myocardial infarctionUnknownInfrarenal aorta77Back and leg pain, and weight lossNeedle biopsy sampling culture of vertebral diskDied16
8M71Myocardial infarction and atrial fibrillationDysuriaInfrarenal aorta7Abdominal pain and feverBacteriological analysis of aneurysmRecovered17
9M75Coronary artery diseaseUnknownInfrarenal aorta8Back painNeedle biopsy sampling culture of the iliopsoas muscleRecovered18
10M72Deep venous thrombosisSweating and flu-like symptomsFemoral artery12Fever and inguinal painCulture of sputum and tissue of aneurysmRecovered19
11M58UnknownUnknownAbdominal aorta36Fever, back pain and weight lossCulture of aneurysm specimenRecovered19
12M71AneurysmMalaiseInfrarenal aorta48FeverCulture of aneurysm specimenRecovered19
13M74Coronary artery disease, hypertension, and diverticulosisConfusion, chills, fever, pancytopenia, and transaminitisInfrarenal aorta12Weakness, diaphoresis and dyspneaCulture of aneurysm specimenRecovered20
14M68UnknownFever and malaiseCarotid artery24Neck swellingNeedle biopsy sampling culture of lymph nodeRecovered21
15M65AneurysmNoneSuprarenal aorta16Abdominal pain, nausea and weight lossCulture of autopsy specimenDied22
16M75UnknownFeverInfratenal aorta and femoral artery32Pain in the hip jointCulture of aneurysm specimenRecovered23
17M67UnknownFever and malaisePopliteal artery23Fever and pain in the kneeClinical diagnosisRecovered24
18M69Appendicitis, colon cancer, and aneurysmUnknownInfrarenal aorta48Back pain and paresisCulture of surgical bone samplingRecovered25
19M80Hypertension and chronic obstructive pulmonary diseaseMalaiseInfrarenal aorta24Fever, malaise, weight loss and back painCulture of aneurysm specimenRecovered26
20M79Coronary artery diseaseUnknownInfrarenal aorta11Fever, fatigue and nigh sweatCulture of aneurysm specimenRecovered27
21M75Hypertension, diabetes, and dyslipidemiaUrosepsisAbdominal aorta and femoral artery24Abdominal and back painCulture of blood and tissue of aneurysmRecovered28
22M79NoneUnknownCarotid artery etc18Neck pain, fatigue and weight lossCulture of abscess surrounding aneurysmDied29
23M75Hypertension, lymphoma, dyslipidemia, and chronic kidney diseaseFever, lethargy, and headachesSuprarenal aorta15Fever, dyspnea, weight lossClinical diagnosisDied30
24M69Coronary artery disease, hypertension, and atrial fibrillationUnknownInfrarenal aorta10Fever and back painPathology of aneurysm specimenRecovered31
25M64Coronary artery disease and diabetesFeverInfrarenal aorta and iliac artery9Fever and abdominal painCulture of pelvic retroperitoneal collectionRecovered32
26M68Gastric cancerFeverInfrarenal aorta7Back painCulture of aneurysm specimenRecovered33
27M73NoneFeverThoracic and abdominar aorta10Abdominal painCulture of aneurysm specimen and abscess of psoas muscleRecovered34
28M70UnknownUnknownAbdominal aorta, iliac artery1Fever and back painCulture of aneurysm specimenRecovered35
29M65NoneFeverThoracic aorta10Fever and back painCulture of sputumRecoveredPresent case

BCG: Bacillus Calmette-Guérin

*The interval: the time interval between the last instillation and the onset of infection

Twenty Nine Reported Cases of Infected Aneurysm by Mycobacterium Bovis. BCG: Bacillus Calmette-Guérin *The interval: the time interval between the last instillation and the onset of infection Long et al. reported that tubercle bacilli may reach the aortic wall in one of three ways: the direct bacterial invasion of the arterial wall with degeneration due to atherosclerosis; the invasion of the adventitia or media by the vasa vasorum; or direct extension from a contiguous focus such as a lymph node or paraspinal abscess (38). Among the patients that are listed in Table, the methods that were used to diagnose M. bovis-induced aneurysms included the culture of the aneurysm (n=16), the culture of the tissue surrounding the aneurysm (n=7), a clinical diagnosis (n=5), [the culture of another tissue type (n=1), the pathological examination of the aneurysm (n=2), and other (n=2)]. In the present case, open surgery was considered to be associated with a high degree of risk. For this reason, histopathological and microbiological examinations were not performed to confirm the diagnosis. Thus, the M. bovis-induced aneurysm was clinically diagnosed using the following evidence: the rapid formation of a thoracic saccular aneurysm with perianeurysmal fluid in only 11 months; the increased size of the low attenuation area surrounding the aortic grafts within 160 days; the decrease in the area of the perianeurysmal fluid after treatment with anti-tuberculosis drugs. M. bovis isolated from sputum was possibly derived from the area of low attenuation surrounding the aortic graft, since the CT images revealed that only the perianeurysmal fluid area adhered to the left lower lobe of the lung and that neither infiltrative changes nor nodules were observed. In addition, oral prednisone might have contributed to the deterioration of the infected aneurysm, thus masking fever. Moreover, the gauze removal surgery might have worsened the perianeurysmal infection. The blood-streaked sputum eventually resolved and the low attenuation mass surrounding the aortic graft decreased in size after treatment with anti-tuberculosis drugs. The treatment of aortic aneurysms due to M. bovis include antimicrobial therapy with or without surgery. M. bovis is usually susceptible to anti-tuberculosis drugs, including rifampicin, isoniazid, and etambutol. It is resistant to pyrazinamide (39). However, the optimal duration of therapy for aortic aneurysms is unknown. Thirteen of the cases of aortic aneurysms that we reviewed included data on the duration of antimicrobial therapy after the diagnosis; 12 cases received antibiotic treatment for ≥9 weeks and 9 cases received antibiotic treatment for ≥12 weeks. Moreover, in some cases, medical therapy alone was inadequate (15, 21). The surgical managements included debridement of the vessel with extra-anatomic bypass and in situ repair with a prosthetic graft; both methods have yielded good results. In the present case, open surgery was considered to be too risky; thus, he was treated using thoracic endovascular aortic repair. Ting et al. reported that a patient with multiple Salmonella infected thoracic aortic aneurysms, was successfully treated by endovascular repair (40). However, in the presence of infection, this technique should therefore be considered on an individual basis. In conclusion, we described a case of a ruptured aortic aneurysm caused by M. bovis, which was challenging to diagnose. In some cases after intravesical BCG therapy, we should consider the possibility of aneurysm caused by M. bovis and it may be important to conduct further evaluations, including surgical and microbiological evaluations.

The authors state that they have no Conflict of Interest (COI).
  35 in total

1.  Diagnosis please. Case 9: mycotic pseudoaneurysm of the abdominal aorta in association with mycobacterial psoas abscess--a complication of BCG therapy.

Authors:  J M LaBerge; R K Kerlan; L M Reilly; T A Chuter
Journal:  Radiology       Date:  1999-04       Impact factor: 11.105

2.  Nearly fatal complications of cervical lymphadenitis following BCG immunotherapy for superficial bladder cancer.

Authors:  H Geldmacher; C Taube; U Markert; D K Kirsten
Journal:  Respiration       Date:  2001       Impact factor: 3.580

3.  Multiple mycotic aneurysms due to Mycobacterium bovis after intravesical bacillus Calmette-Guérin therapy.

Authors:  Raphael Coscas; Jean-Benoît Arlet; Denis Belhomme; Jean-Noël Fabiani; Jacques Pouchot
Journal:  J Vasc Surg       Date:  2009-08-05       Impact factor: 4.268

Review 4.  Tuberculous mycotic aneurysm of the aorta: review of published medical and surgical experience.

Authors:  R Long; R Guzman; H Greenberg; J Safneck; E Hershfield
Journal:  Chest       Date:  1999-02       Impact factor: 9.410

5.  Surgical pathology of infected aneurysms of the descending thoracic and abdominal aorta: clinicopathologic correlations in 29 cases (1976 to 1999).

Authors:  Dylan V Miller; Gustavo S Oderich; Marie-Christine Aubry; Jean M Panneton; William D Edwards
Journal:  Hum Pathol       Date:  2004-09       Impact factor: 3.466

6.  Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer.

Authors:  D L Lamm; P M van der Meijden; A Morales; S A Brosman; W J Catalona; H W Herr; M S Soloway; A Steg; F M Debruyne
Journal:  J Urol       Date:  1992-03       Impact factor: 7.450

Review 7.  Mycotic vascular infections of large arteries with Mycobacterium bovis after intravesical bacillus Calmette-Guérin therapy: case report.

Authors:  M H Seelig; W A Oldenburg; P J Klingler; M L Blute; P C Pairolero
Journal:  J Vasc Surg       Date:  1999-02       Impact factor: 4.268

8.  Mycotic abdominal aortic aneurysm induced by immunotherapy with bacille Calmette-Guérin vaccine for malignancy.

Authors:  J M Woods; J Schellack; M T Stewart; D R Murray; S W Schwartzman
Journal:  J Vasc Surg       Date:  1988-06       Impact factor: 4.268

Review 9.  Ruptured mycotic abdominal aortic aneurysm secondary to Mycobacterium bovis after intravesical treatment with bacillus Calmette-Guérin.

Authors:  Gregory E J Harding; D Kirk Lawlor
Journal:  J Vasc Surg       Date:  2007-07       Impact factor: 4.268

Review 10.  Infected (mycotic) aneurysms: spectrum of imaging appearances and management.

Authors:  Wai-Kit Lee; Peter J Mossop; Andrew F Little; Gregory J Fitt; Jhon I Vrazas; Jenny K Hoang; Oliver F Hennessy
Journal:  Radiographics       Date:  2008 Nov-Dec       Impact factor: 5.333

View more
  8 in total

1.  BCGitis after Bacille Calmette-Guerin intravesical administration from two referral centers: clinical characteristics and risk factors.

Authors:  Ilaria De Benedetto; Ambra Barco; Marianna Rossi; Giuseppe Lapadula; Tommaso Lupia; Paolo Bonfanti; Stefano Bonora; Giovanni Di Perri; Andrea Calcagno
Journal:  Infez Med       Date:  2022-06-01

2.  Tuberculosis Aortitis and Mycotic Pseudo-aneurysm of the Infra-renal Aorta after Intravesicular BCG Therapy.

Authors:  Nathan Gamble; Robert Blair; Sam Gray; Michael Hunter; Denis Harkin
Journal:  Ulster Med J       Date:  2022-06-15

Review 3.  Tuberculous Aortic Aneurysm - A Review.

Authors:  Abdulmajeed Altoijry
Journal:  Braz J Cardiovasc Surg       Date:  2022-05-23

4.  Rare case of a proximal descending thoracic aorta mycotic aneurysm following intravesical BCG injections for the treatment of bladder cancer.

Authors:  Luis Ribeiro; Saissan Rajendran; Katherine Stenson; Ian Loftus
Journal:  BMJ Case Rep       Date:  2019-12-15

5.  Rapid detection of bacille Calmette-Guérin-associated mycotic aortic aneurysm using novel cell-free DNA assay.

Authors:  Vignesh Vudatha; Mark Ranson; Lily Blair; Asim A Ahmed
Journal:  J Vasc Surg Cases Innov Tech       Date:  2019-04-28

6.  Aortic aneurysm and aortic graft infection related to Mycobacterium bovis after intravesical Bacille Calmette-Guérin therapy-a case series.

Authors:  M Buerger; S Kapahnke; S Omran; M Schomaker; M Rief; A Greiner; J P Frese
Journal:  BMC Surg       Date:  2021-03-17       Impact factor: 2.102

7.  Successful endovascular treatment of abdominal aortic rupture secondary to bacillus Calmette-Guérin vaccine.

Authors:  Andrew E Liechty; Albert Pacifico; Peter Brant-Zawadzki
Journal:  J Vasc Surg Cases Innov Tech       Date:  2021-11-22

Review 8.  Therapeutic effectiveness of tuberculous aneurysm and risk factors for mortality: a systematic review.

Authors:  Shengwu Yi; Lingjie Sheng; Wei Li
Journal:  Gen Thorac Cardiovasc Surg       Date:  2022-04-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.